bpc-157 in functional medicine & The Gut-Brain Axis: A Practitioner's Definitive Review of the Evidence Peptide Therapy for Inflammation: A

Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, et al

To date, MK-677 has yet to pass Phase II clinical trials and is classified as an Investigational New Drug by the US FDA

International scheduling Australia's Therapeutic Goods Administration (interim decision, April 2024) and New Zealand's Medsafe (Medicines Classification Committee, June 2025) have moved to schedule BPC-157 as a prescription-only medicine, despite its unavailability through legitimate prescription

Vials stored in unheated spaces, near windows, or in garages during winter can freeze

Hunt A, Schnknecht P, Henze M, Seidl U, Haberkorn U, Schrder J

Furthermore, every patient will have a slightly different rate of metabolism for the drug, and thus the way they respond, hence why microdosing works